Tuberculosis (TB) continues to be one of the most serious infectious diseases in the world, accounting for 1.7 million deaths in 2019. Approximately a quarter of the world’s population is infected with the pathogen Mycobacterium tuberculosis in latent form. TB is of enhanced concern when combined with other diseases, such as HIV and Covid-19.
A further concern is the rapid spread of multi drug resistant- (MDR) and extensively drug resistance (XDR) TB, gradually rendering the standard drugs ineffective and requiring the development of new drugs. The WHO End TB Strategy targets the year 2030 as the end of the TB epidemic. Given the current trends, the objective is predicted to fall short as underlined by the Stop TB Partnership saying that “The Clock is Ticking”.
The 2nd Annual Symposium New approaches to TB Drug Discovery will feature presentations from speakers from around the world who have made significant advances in TB research. The virtual event aims to present novel concepts and provide a platform for vibrant and open discussions between senior scientists, postdoctoral fellows and students alike.
The symposium is organized by members of TOPNet (Targeting Oxidative Phosphorylation Network), a TB-excellence cluster funded by the Singapore National Research Foundation, at NTU, and the Centre for Drug Discovery and Development (CDDD), Sathyabama Institute of Science and Technology, India.
Click here for the event page.
Register for the symposium here.